| (-)-Isoproterenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-Citronellol |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| (-)-Syringaresinol |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| (-)-Isoproterenol hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Myrtenal |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salicylate choline |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (20S)-18,20-Epoxydigitoxigenin α-L-thvetoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (3S)-Tanzisertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (5R)-5-Hydroxytriptolide |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| (6R,7R)-Epoxy-1-oleanen-3-ol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-C-HDMAPP ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E/Z)-Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| (R)-5,7-Dimethoxyflavanone |
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| (R)-Benpyrine |
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| (Rac)-Benpyrine |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| (Rac)-BIO8898 |
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| (Rac)-Apremilast-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-Elobixibat |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Z)-KC02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-Perillaldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
96.70% |
| (±)-Taxifolin |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| 1,2-DLPC |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 1,4-Naphthoquinone |
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| 1,4-Naphthoquinone-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| 1,4-Dicaffeoylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| 10-OAHSA |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| 10-Hydroxy-2-decenoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| 10-Hydroxydecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| 12-Hydroxydehydroabietic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Nitrolinoleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Oxo phytodienoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Oxo phytodienoic acid (≥90%) |
|
|
|
|
|
|
|
|
|
|
|
|
92.2% |
| 19-epi-Scholaricine |
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| 2'-Fucosyllactose |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| 2'-Acetylacteoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| 2′-Hydroxy-5′-methoxyacetophenone |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| 2-(2,6-Dioxopiperidin-3-yl)phthalimidine |
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| Fisetin quarterhydrate |
|
|
|
|
|
|
|
|
|
|
|
|
95.89% |
| 2-ARA-LysoPtdEtn |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Hydroxy Imiquimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Ketoglutaric acid potassium |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 2-O-Methyl PAF C-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-O-Methylatromentin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2141-V11 |
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| 3-O-Caffeoyl-5-O-feruloylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4′-Hydroxywogonin |
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| 4,5-Dehydro-6-oxoallosecurinine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Methoxycinnamic acid ethyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| 4-Allylcatechol |
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| 5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5-Methoxytryptophol |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Leucrose |
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| 5-O-Methylvisammioside |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| 7-O-Galloyl-D-sedoheptulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7-O-Methyl glabranin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8-(4-(Trifluoromethyl)anilino)quercetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 8-(6,7-Dihydroxy-3,7-dimethyl-2E-octenyloxy)psoralen |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loganic acid 6′-O-β-D-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 9-Methoxycanthin-6-one |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| A-802715 |
|
|
|
|
|
|
|
|
|
|
|
|
98.45% |
| a15:0-i15:0 PE |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABBV-154 |
|
|
|
|
|
|
|
|
|
|
|
|
96.23% |
| ABBV-3373 |
|
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| ABI793 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Abiprubart |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| ABS-101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Pro-Gly-Pro-OH |
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Acetoxycycloheximide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetyl tetrapeptide-2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Acimtamig |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Actarit |
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| AD-35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADG-106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adrenocorticotropic hormone |
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Adrenocorticotropic hormone TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| AF-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Afimkibart |
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| AGEN-2373 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt/NF-κB/JNK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt/NF-κB/MAPK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aloeresin G |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alphitolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| AMG-172 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AMG-228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AMG-966 |
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| AN-2898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anhydro-Ouabain |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD160 Antibody (MAT 302) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD27 Antibody (M2177) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD27 Antibody (M2191) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD30L Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD40 Antibody (G28.5) |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-DR3 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-FasL Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 115 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 116 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 35 |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Anti-inflammatory agent 41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 61 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 95 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Monkey/Human CD40L/CD154 Antibody (5C8) |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) |
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Anti-Mouse 4-1BB/CD137 Antibody (3H3) |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) |
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) |
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse BAFF-R Antibody (9B9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD120a Antibody (55R-170) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD120a Antibody (55R-593) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD27 Antibody (RM27-3E5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD40 Antibody (FGK4.5/FGK45) |
|
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CD40L/CD154 Antibody (MR-1) |
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Anti-Mouse CD70 Antibody (TAN 1-7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse DR5/CD262 Antibody (MD5-1) |
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Anti-Mouse Fas Ligand Antibody (MFL3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse Galectin-9 Antibody (RG9-1) |
|
|
|
|
|
|
|
|
|
|
|
|
95.64% |
| Anti-Mouse GITR (D265A) Antibody (DTA-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) |
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| Anti-Mouse GITR Antibody (DTA-1) |
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) |
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| Anti-Mouse TNFR2 Antibody (TR75-54.7) |
|
|
|
|
|
|
|
|
|
|
|
|
98.864% |
| Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12) |
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Anti-TNFRSF21/DR6/CD358 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Anti-TNFRSF7/CD27 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-TNFSF2/TNFa Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-TNFSF2/TNFa Antibody (hMAK195) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-TNFSF9/4-1BBL Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibiofilm agent-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibiofilm agent-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antileishmanial agent-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aplitabart |
|
|
|
|
|
|
|
|
|
|
|
|
97.024% |
| ApoA-I mimetic peptide 5A |
|
|
|
|
|
|
|
|
|
|
|
|
97.43% |
| Apratastat |
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| aptTNF-α sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AQX-016A |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| AR420626 |
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Aritinercept |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Arucadiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ARX305 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AS1940477 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASB16165 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASK1-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Asobamast |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASP1951 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASP8374 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASP9831 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aspartyl-alanyl-diketopiperazine |
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| Asperflavin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Asunercept |
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| Ataquimast |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Atenastobart |
|
|
|
|
|
|
|
|
|
|
|
|
98.473% |
| Atrosab |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Atrosimab |
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| AX-024 |
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| AX-024 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| AX-024 hydrochloride (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Bisabolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balertatug |
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Balinatunfib |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| BAY-356 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BC011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BChE-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BCMA72-80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Belantamab (FUT8-KO) |
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| Benpyrine |
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Benzo-17R-RvD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benzydamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berkeleyacetal C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Betamethasone succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BI-113823 |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| BI-1808 |
|
|
|
|
|
|
|
|
|
|
|
|
97.75% |
| BI-1910 |
|
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| BI-655064 |
|
|
|
|
|
|
|
|
|
|
|
|
98.56% |
| BIHC |
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| BIIB023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIIB036 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIM-46174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIO8898 |
|
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| Bioymifi |
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Bleselumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| BML-280 |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| BMS-279700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-561392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-561392 formate |
|
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| BMS-566394 |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| BMS-751324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-986156 |
|
|
|
|
|
|
|
|
|
|
|
|
97.11% |
| BMS-986178 |
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| BMS-986325 (anti-CD40) |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Boserolimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| BRD4 Inhibitor-38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BRD4-BD1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Brentuximab |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Brivekimig |
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Broussonin E |
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| BSF2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BU224 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
96.96% |
| Butrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| C 87 |
|
|
|
|
|
|
|
|
|
|
|
|
98.16% |
| C25-140 |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| C2NP sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| C5 Lenalidomide |
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Calenduloside E |
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Callistephin chloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Candidusin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casuarinin |
|
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| Cathelicidin-PY |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAY10512 |
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| CAY10789 |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| CBS-3408 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CBS001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CC-1069 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD28-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD28-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDC801 |
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| CDN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDX-1140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cenzestotug |
|
|
|
|
|
|
|
|
|
|
|
|
99.447% |
| Ceramide 3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Ceramide 3-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| CH-100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chamissonolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chloranthalactone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIAC101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ciltistotug |
|
|
|
|
|
|
|
|
|
|
|
|
95.376% |
| Cinrebafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| cis-Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CJ-14897 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CKD-712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cl-Necrostatin-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cleomiscosin A |
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Cloricromen hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Cm-CATH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CO delivery molecule 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Coelonin |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Conatumumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Cot-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COVA322 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-66 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/5-LOX-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/CaV2.2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CPI-1189 |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| CRAMP (mouse) |
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| Crocatin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CRX 527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CSF1R-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CT-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| CT-133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CTB006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cudraflavone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CX-659S |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytokine-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CZEN-002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| D-chiro-Inositol |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| D-Trimannuronic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Darutoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Dazodalibep |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| DBM 1285 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DCLK1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DCVC |
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Decarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Defensin HNP-1 human |
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
| Defensin HNP-1 human TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Delmitide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Delmitide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Deoxyartemisinin |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Desipramine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Desoxo-narchinol A |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| DHU-Se1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dichotomine C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethanolamine |
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Diethanolamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diethylcarbamazine |
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Dihydrodehydrodiconiferyl alcohol |
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Diprovocim |
|
|
|
|
|
|
|
|
|
|
|
|
98.82% |
| Divaricatol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DLX-105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DN203316 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DOR agonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dordaviprone |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| DPP-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DPP-4-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DPP4-In hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRI-C21041 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRI-C21041 DIEA |
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| DRI-C21045 |
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| DRI-C25441 |
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| DSTYSLSSTLTLSK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| DT-5461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Duvakitug |
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Eftozanermin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| EGFR-IN-144 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/Cytokine-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGR-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| EJMC-1 |
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| Elipunercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EM-163 |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Emfizatamab |
|
|
|
|
|
|
|
|
|
|
|
|
95.495% |
| Emirodatamab |
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| Emunkitug |
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Emzotamig |
|
|
|
|
|
|
|
|
|
|
|
|
96.02% |
| Endothelin 1 (swine, human), Alexa Fluor 488-labeled |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Enristomig |
|
|
|
|
|
|
|
|
|
|
|
|
98.447% |
| Epaldeudomide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ephemeranthol A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Episappanol |
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Epobis |
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Eps8 peptide 327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ER-464195-01 |
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| ETI41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ETI60 |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Etiprednol dicloacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EU-102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Evunzekibart |
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| Exlinkibart |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| F 991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fasentin |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| FASN/SCD-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FFP-104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FGA139 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FIP22 |
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Fosimdesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fowlicidin-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FPA154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Frexalimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| FTO-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FuBIG |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FXR agonist 17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| FXR agonist 18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GABAAR/5-HT2AR modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gamgertamig |
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Gamma-glutamylcysteine ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GAP214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GB-223 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GE1111 |
|
|
|
|
|
|
|
|
|
|
|
|
95.73% |
| GEN-1053 |
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Geranial |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Geraniin |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Gimistotug |
|
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| Ginsenoside Rg4 |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Giraldoid B |
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| Givastomig |
|
|
|
|
|
|
|
|
|
|
|
|
98.556% |
| GlcNAc-MurNAc |
|
|
|
|
|
|
|
|
|
|
|
|
95.37% |
| GLPG4471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GLPG4970 |
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Glucocorticoid receptor agonist-3 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Glucocorticoid receptor agonist-4 Ala-Ala-Mal |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GNE-5472 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gnetifolin E |
|
|
|
|
|
|
|
|
|
|
|
|
97% |
| Gnetucleistol F |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPR68 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK-3174998 |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| GSK1995057 |
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| GSK2245035 |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| GSK2245035 maleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK2800528 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK2862277 |
|
|
|
|
|
|
|
|
|
|
|
|
97.85% |
| GSK699 |
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| GSK789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GW-3333 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GW-405833 |
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| GW405833 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| GYY4137 |
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| GYY4137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GYY4137 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| hCBE-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6-IN-80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDMAPP triammonium |
|
|
|
|
|
|
|
|
|
|
|
|
90.0% |
| Hecubine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HeFi-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hibiscetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hispidol |
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| HLX51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| hMAO-B-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HMGB1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| HS-276 |
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| HS-276 formic |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-276 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSP90-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrangeic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydrostatin-TL1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IA-14069 |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Ianalumab (FUT8-KO) |
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| IBI-325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IBI356 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IBI37G5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1/TDO-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDT |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IK-862 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IKK 16 |
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| IKK 16 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Ilexgenin A |
|
|
|
|
|
|
|
|
|
|
|
|
98.37% |
| Iminostilbene-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immuno modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inezetamab |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Ingitamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRAK4-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRF5-CPP5 |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| ISB2001 |
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| ISIS 104838 |
|
|
|
|
|
|
|
|
|
|
|
|
91.02% |
| ISIS 104838 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
96.37% |
| ISIS 104838 sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoconiferinoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoeucommin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isopongaflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoquinoline |
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ispectamab |
|
|
|
|
|
|
|
|
|
|
|
|
98.102% |
| IW927 |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| JAK-IN-39 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK05 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ-64164711 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ525 |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| JNK2/MKK7 PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNU-0921 |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| JR4-187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JWX-A0108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| K-8012 |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferol 3-O-sophoroside |
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| KB-R7785 |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| KC01 |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Kdo2-Lipid A ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
95.2% |
| Keap1/Nrf2/ARE activator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KF24345 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KGYY15 |
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Koaburaside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KOR agonist 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KR-33493 |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| KSI-028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KZR-8445 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-Norvaline |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L-Norvaline-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| γ-Glutamylvaline |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| L-Threonic acid magnesium |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L524-0366 |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| L6H21 |
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Lacto-N-neotetraose |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| LAGi-DEL |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lavandoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| LBL-019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LC-PDA-01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LCC-12 formate |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| LEAP-2 |
|
|
|
|
|
|
|
|
|
|
|
|
97.75% |
| LEESGGGLVQPGGSMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LEESGGGLVQPGGSMK acetate |
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| LEESGGGLVQPGGSMK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lenercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Linalool,98% (stabilized with MEHQ) |
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| LMP-420 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LPZ-51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LSD1-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lss-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lucidone |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY 303511 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY 303511 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY 303511 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| LY2775240 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LZ-07 |
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| M04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| M199 |
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| M802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maceneolignan A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maltotetraose |
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Malvidin-3-glucoside chloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Maxadilan |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MB-314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MCB-294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MCB-36 |
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| MDL 201112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MDX-1115 |
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| MDX-1401 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MEDI-5083 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MEDI-7352 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MG-C-30 |
|
|
|
|
|
|
|
|
|
|
|
|
95.55% |
| MG-T-19 |
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Mitochonic acid 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-0873 |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| MK-1248 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-4166 |
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| MM-102 |
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| MMP-9-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| MN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Monoolein |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Mosloflavone |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| MR2938 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| MSB013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mumefural |
|
|
|
|
|
|
|
|
|
|
|
|
95.17% |
| N-Formyl-Met-Leu-Phe |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| N-Palmitoyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-acetyldopamine |
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Naamidine J |
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Naphazoline-d4 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NC762 |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Necrosulfonamide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| NecroX-7 |
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Neral |
|
|
|
|
|
|
|
|
|
|
|
|
97.87% |
| Nesfrotamig |
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Neuroprotective agent 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NF-κB-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NGM-438 |
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| NIK-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nitroparacetamol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NMB04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NO-Pravastatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOD2 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Norketotifen |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NPSR1 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NS-6740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NS-6740 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 15830 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC243928 mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Nuvustotug |
|
|
|
|
|
|
|
|
|
|
|
|
95.36% |
| ODE-(S)-HPMPA formate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ODN 1585 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ODN 1585 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
92.48% |
| ODN M362 |
|
|
|
|
|
|
|
|
|
|
|
|
96.01% |
| ODN M362 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| OH14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oleracone |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Olevaprubart |
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Omtriptolide sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ON203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Onfekafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ONO-4007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Opinercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| OX118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oxazolone |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Oxidized low density lipoprotein (Human) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ozekibart |
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| p38α-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Paeoniflorin-6′-O-benzene sulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pamlectabart |
|
|
|
|
|
|
|
|
|
|
|
|
97.00% |
| Panaxytriol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Papiliocin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Patrinoside aglucone |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PBI-1393 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE/TRPA1/CHIT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4B-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4B-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4D inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pentadecane-d32 |
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| Peptide HV2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-05230905 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-06745013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PF-07329640 |
|
|
|
|
|
|
|
|
|
|
|
|
95.25% |
| PF-4878691 |
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| PHI-501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phosphodiesterase-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| PIYLGGVFQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pochonin D |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Podentamig |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pongamol |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Povetacicept |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| PPARγ agonist 20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PQA-18 |
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| PR200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Progranulin modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HDAC6 degrader 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC JAK1/2 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| PROTAC PDE4 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PTD |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PTX-35 |
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Punicic acid |
|
|
|
|
|
|
|
|
|
|
|
|
98.5% |
| Pyrrothiogatain |
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| QNZ |
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| Quin-C7 |
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| R-03201195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-7050 |
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| R1-ICR-5 |
|
|
|
|
|
|
|
|
|
|
|
|
98.73% |
| RAGE406R |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ramantamig |
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Ranevetmab |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RANK-derived TRAF6 inhibitor |
|
|
|
|
|
|
|
|
|
|
|
|
|
| REGN6569 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion |
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-Talmapimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-(1S,2R)-Dihydro bupropion-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Resolvin D2 n-3 DPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revamilast |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RG-7212 (RO5458640) |
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| RIPK1-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RIPK2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rosavin |
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Rozibafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
96.98% |
| RP-182 |
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| RP-182 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RP-832c |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| RPR-200765A methanesulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sabialimon P |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Sappanone A |
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Sar10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SBT-040 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SC-67655 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schisantherin B |
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| sEH inhibitor-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| sEH/AChE-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Semapimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Semapimod tetrahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Senlizumab |
|
|
|
|
|
|
|
|
|
|
|
|
95.09% |
| Shizukaol B |
|
|
|
|
|
|
|
|
|
|
|
|
96% |
| SHP2-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Siegeskaurolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SIK2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| SIM-0235 |
|
|
|
|
|
|
|
|
|
|
|
|
95.09% |
| Sinulatumolin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sinulatumolin D |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sinulatumolin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SKF 104351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SLP7111228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SLP7111228 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| SMAP-29 |
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| SMI 6860766 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-14a |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-C409 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-L11-R |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-Z1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU127 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Solabafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
97.17% |
| Solaprubart |
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Sotigalimab |
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| SPD304 |
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| SPD304 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Spirohypertone B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SQ 29548 |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| SR-318 |
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| ST-899 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT1/3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Stigmasta-3,5-dien-7-one |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| STING agonist-45 |
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| STING-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| Sudachitin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sugiol |
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Surovatamig |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| SYLQDSVPDSFQD |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sym029 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| t9,t11,c15-CLNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TACE-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Talaromyketide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tanimilast |
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| TAPI-0 |
|
|
|
|
|
|
|
|
|
|
|
|
97.06% |
| TAPI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| TAS266 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-327 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-N24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tavolixizumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Taxamairin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBE 31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBL-CLN1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBPH |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Tebentafusp |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Tegoprubart |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Teneliximab |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Tepoditamab |
|
|
|
|
|
|
|
|
|
|
|
|
≥99% |
| Terameprocol |
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| Theasinensin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline L-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thunberginol C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TL-895 |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| TLR7 agonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| TLR7/8 agonist 14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 6 |
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| TLR9 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 diformate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TMI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| TNF-alpha-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α (10-36), human TFA |
|
|
|
|
|
|
|
|
|
|
|
|
98.23% |
| TNF-α (31-45), human |
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| TNF-α (31-45), human TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| TNF-α (46-65), human |
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| TNF-α (46-65), human TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| TNF-α-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| TNF-α-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| TNF-α-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| TNF-α-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| TNF-α-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| TNF-α-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF-α/IL-1β-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNF/IFN-γ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| TNFR1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNFR1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TNIK-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
98.28% |
| TNX-1500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TQB2916 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRAF-STOP inhibitor 6877002 |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| TREM-1 inhibitory peptide GF9 |
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Tributyrin |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Trichodimerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trigraecum |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tripeptide-41 |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Triptobenzene H |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRPM8 antagonist 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRPV1 antagonist 10 |
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| TRX-518 |
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Tryptanthrin |
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Tulinercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tulisokibart |
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| UBP1213 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| UCB-5307 |
|
|
|
|
|
|
|
|
|
|
|
|
97.09% |
| UCB-6876 |
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| UCB-9260 |
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Umckalin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Undecane |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Undecane-d24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Urelumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.138% |
| UTL-5g |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| VA06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Variegatic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Varlilumab (anti-CD27) |
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| VB-85247 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vedastotug |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Verproside |
|
|
|
|
|
|
|
|
|
|
|
|
|
| VGX-1027 |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Vialinin A |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Vitexin-4''-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Vonlerizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vonsetamig |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Vorsetuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| VR11 aptamer |
|
|
|
|
|
|
|
|
|
|
|
|
|
| VTX-0811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Withaphysalin A |
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| WK2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| WP9QY |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| WP9QY TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Xanthine oxidase-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xanthine oxidase-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ximoprofen |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xirestomig |
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| XmAb-2513 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| XmAb5485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xylobiose |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Y2641 |
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Yangambin |
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| Z-3578 |
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Zaptuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| ZJK-807 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Alethine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Anhydroicaritin |
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| β-Carotene-15,15'-epoxide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Eudesmol |
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Gamma-glutamylcysteine |
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
|
|
|
|
|
|
|
|
96.68% |
| Trilobatin |
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Trifolirhizin |
|
|
|
|
|
|
|
|
|
|
|
|
98.37% |
| Tris(2-chloroethyl) phosphate |
|
|
|
|
|
|
|
|
|
|
|
|
97.07% |
| Tris(2-chloroethyl)phosphate-d12 |
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Utomilumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Theophylline sodium acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| N,N-Diethylacetamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diminazene |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Iminostilbene |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Geniposidic acid |
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| Ginsenoside Rc |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Ginsenoside Rh1 |
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| Talmapimod |
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| Talmapimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tabalumab |
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Ianalumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Iscalimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Iratumumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Varlilumab |
|
|
|
|
|
|
|
|
|
|
|
|
96.09% |
| Enavatuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| Etanercept |
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Crebanine |
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Grossamide |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 6:2 Fluorotelomer alcohol |
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Gaultherin |
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Linvoseltamab |
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Licaminlimab |
|
|
|
|
|
|
|
|
|
|
|
|
96.10% |
| Nootkatone |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Prim-O-glucosylcimifugin |
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Ruplizumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Lucatumumab |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Deacetylasperulosidic Acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Demethylwedelolactone |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Deapi-platycodin D3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Bicyclol |
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Mutanolysin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| rel-Cleroindicin F |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Linarin |
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Kukoamine A |
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Elranatamab |
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| Selicrelumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Remtolumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Karacoline |
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Ceftiofur |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ceftiofur hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| Ceftiofur sodium |
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Ceftiofur-d3 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nerelimomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ozoralizumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Opamtistomig |
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Omeprazole |
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Omeprazole sulfone (methoxy-d3) |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Omeprazole-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole sodium |
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Omeprazole-d3 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole magnesium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omeprazole-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Omeprazole-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| Omeprazole-d3-1 |
|
|
|
|
|
|
|
|
|
|
|
|
95.09% |
| Amcinonide |
|
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Microhelenin C |
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Cornuside |
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Parishin C |
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Conbercept |
|
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Isoforskolin |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Isoquinoline-15N |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cardenolide B-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Golimumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Manumycin A |
|
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Toralizumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Ragifilimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Ravagalimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Neochlorogenic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Neomangiferin |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Ecliptasaponin A |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Omtriptolide |
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| Placulumab |
|
|
|
|
|
|
|
|
|
|
|
|
96.84% |
| Siaresinolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tecaginlimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Tenilsetam |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Tibulizumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| Tiratricol |
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| 7,3',4'-Tri-O-methylluteolin |
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Letolizumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Myricitrin |
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Diethylcarbamazine citrate |
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Saikosaponin B1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Roburic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Eucalyptol-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eucalyptol |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Mulberroside A |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Ethyl palmitate |
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Arecaidine |
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Aurantio-obtusin |
|
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| Dodecane |
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Pentadecane |
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Pentadecane (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Flurbiprofen axetil |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Flumethasone |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Cloricromen |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lornoxicam |
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Desloratadine |
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Kaolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Telitacicept |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Zigakibart |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Alisol F |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Rozanolixizumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Trehalose 6-behenate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lysozyme |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Fisetin-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fisetin |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Ganoderic acid C1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taurohyodeoxycholic acid-d4 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Taurohyodeoxycholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Taurohyodeoxycholic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Tanfanercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lard oil |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Relfovetmab |
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Resatorvid |
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Licoricesaponin G2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Sinensetin |
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Thiophanate-Methyl |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Methylthiouracil |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Nafamostat mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Beauvericin |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Atractylenolide I |
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Kaempferol-3-O-glucorhamnoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Desipramine-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Desipramine-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Desipramine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Benzydamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Naphazoline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Nafamostat hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nifuratel |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Naphazoline nitrate |
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Chondroitin sulfate (from chicken) |
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Fosfenopril |
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Fosfenopril-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chikusetsusaponin IVa methyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mitazalimab |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Shikonin |
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Roquinimex |
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Grosvenorine |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Madecassic acid |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Sesamoside |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Taxifolin |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Fluorene |
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| Fluorene-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Infliximab |
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| Infliximab (Anti-TNF-α) |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Poricoic acid B |
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| Skimmin |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Theophylline |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Theophylline-13C2,d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Theophylline (sodium glycinate) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orientin |
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Cynaropicrin |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Naphazoline |
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Nafamostat |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Terpinolene |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Astilbin |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Cordycepin |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Balanophonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Doxorubicinone |
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| Cetrelimab |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Edpetiline |
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Belantamab |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Belimumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Baminercept |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Benufutamab |
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Peimine |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Certolizumab pegol |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Coenzyme Q0 |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Dacetuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
95.37% |
| Ergosterol peroxide |
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Forsythoside B |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Zymosan (ZM), 95% |
|
|
|
|
|
|
|
|
|
|
|
|
96.11% |
| Licarin A |
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Eupalinolide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sciadopitysin |
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Atacicept |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Apremilast |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Apremilast-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Apremilast-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apremilast-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adalimumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| Afelimomab |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Citronellol |
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Citronellol-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loganin |
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Homoplantaginin |
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Homovanillyl alcohol |
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Lubiprostone-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lubiprostone |
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Muscone |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Aflatoxin G1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Negletein |
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Hecogenin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |